Document is current
Any future updates will be listed below
-
Authors
Demanse, D.
Saxer, F.
Gazit, S.
Patalon, T.
Schieker, M.
-
Funding
Funding for this research was provided by:
Novartis Institutes for BioMedical Research (BASICHR0062)
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 9 March 2026
First Online: 17 March 2026
Declarations
:
: Ethics approval has been obtained from the Maccabi Institutional Review Board (IRB, The Institutional Review Board | המזכירות האקדמית | אוניברסיטת תל אביב, last accessed March 5 2025) (ref. MHS-0126-22). Informed consent to participate was waived due to the retrospective and anonymized nature of the study. The study followed applicable law, good clinical practice and the tenets of the Declaration of Helsinki.
: Not applicable.
: Franziska Saxer is employee and shareholder of Novartis, she is affiliated to the University Basel and member of the European Union Medical Devices - Expert Panel section Orthopaedics, traumatology, rehabilitation, rheumatology. David Demanse is employee and shareholder of Novartis. Sivan Gazit and Tal Patalon do not have no competing interests. Matthias Schieker is employee and shareholder of Novartis, he is affiliated to LMU Munich and owner of LivImplant GmbH.
